Notch Inhibitors
1 drugsAbout Notch
Notch receptors are transmembrane proteins mediating cell-cell communication, influencing cell fate during development and tissue homeostasis. As a key signaling pathway, Notch is involved in cell proliferation, differentiation, and apoptosis.
Aberrant Notch signaling is implicated in various diseases, making it a potential drug target. Currently, there is no genetic evidence available linking Notch to specific diseases in this dataset.
There is one FDA-approved drug, OGSIVEO, targeting the Notch pathway as a small molecule. SPRINGWORKS is the only company with an approved Notch-targeting drug, indicated for 'other' therapeutic areas.
Top Notch Drugs
SPRINGWORKS is the only company with an approved drug targeting Notch.
The lack of competition presents an opportunity for new entrants in the Notch-targeting space.
Notch Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Notch, using small molecule modality.
Explore alternative modalities like antibodies or biologics to differentiate from existing therapies.
Notch Clinical Trials 21 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Notch. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 3 | 1 | 8 | 75% |
| Phase 2 | 7 | 1 | 1 | 5 | 50% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Notch Drug Approval Timeline (2023 - 2023)
The first and most recent drug approval for a Notch target was OGSIVEO in 2023.
Recent approval suggests renewed interest, but limited history indicates market immaturity.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 13 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Notch. A trial counts if an approved drug acting on Notch is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.